Frontiers of Medicine in China

, Volume 4, Issue 3, pp 323–328 | Cite as

Inhibition of NF-kappa B can enhance Fas-mediated apoptosis in leukemia cell line HL-60

Research Article
First Online:
Received:
Accepted:

Abstract

This study explored the effects of nuclear factor-kappa B (NF-κB) inhibitor Bay 11-7082 on Fas/FasL system and Fas-mediated apoptosis in cell line HL-60 cells. The mRNA and protein levels of Fas, FasL, and X-linked inhibitor of apoptosis protein (XIAP) were detected by reverse transcription-polymerase chain reaction (RT-PCR) and flow cytometry (FCM); the level of sFasL was evaluated by enzyme-linked immunosorbent assay (ELISA); and apoptosis was determined by FCM. After treatment with Bay 11-7082, the mRNA and protein levels of FasL and XIAP in HL-60 cells were significantly lower than in the controls (P < 0.05), but the mRNA and protein levels of Fas and sFasL did not change significantly (P > 0.05). Apoptotic rate of HL-60 cells treated with Bay 11-7082 was significantly higher than in the controls (P < 0.05). Therefore, we conclude that Bay 11-7082 can enhance Fas-mediated apoptosis in HL-60 cells by downregulating FasL and XIAP levels.

Keywords

nuclear factor-kappa B Fas/FasL system HL-60 Bay 11-7082 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Friesen C, Herr I, Krammer P H, Debatin K M. Involvement of the CD95(APO-1/Fas)receptor/ligand system in drug-induced apoptosis in leukaemia cell. Nature Med, 1996, 2(5): 574–577CrossRefPubMedGoogle Scholar
  2. 2.
    Kim K M, Lee K, Hong Y S, Park H Y. Fas-mediated apoptosis and expression of related genes in human malignant hematopoietic cell. Exp Mol Med, 2000, 32(4): 246–254PubMedGoogle Scholar
  3. 3.
    Kordes U, Krappmann D, Heissmeyer V, Ludwig W D, Scheidereit C. Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia, 2000, 14(3): 399–402CrossRefPubMedGoogle Scholar
  4. 4.
    Qin Y, Camoretti-Mercado B, Blokh L, Long C G, Ko F D, Hamann K J. Fas Resistance of Leukemic Eosinophils Is Due to Activation of NF-κB by Fas Ligation. J Immunol, 2002, 169(7): 3536–3544PubMedGoogle Scholar
  5. 5.
    Bueso-Ramos C E, Rocha F C, Shishodia S, Medeiros L J, Kantarjian H M, Vadhan-Raj S, Estrov Z, Smith T L, Nguyen M H, Aggarwal B B. Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia. Hum Pathol, 2004, 35(2): 246–253CrossRefPubMedGoogle Scholar
  6. 6.
    Hafez M, Al-Tonbary Y, El-Bayoumi M A, Hatem N, Hawas S, Mansour A, Marzouk I, Hafez M M, Yahia S, Farahat N. Markers of apoptosis and proliferation related gene products as predictors of treatment outcome in childhood acute lymphoblastic leukemia. Hematology, 2007, 12(3): 209–218CrossRefPubMedGoogle Scholar
  7. 7.
    Qin Y, Camoretti-Mercado B, Blokh L, Long C G, Ko F D, Hamann K J. Fas Resistance of Leukemic Eosinophils Is Due to Activation of NF-κB by Fas Ligation. J Immunol, 2002, 169(7): 3536–3544PubMedGoogle Scholar
  8. 8.
    Barnhart B C, Pietras E M, Algeciras-Schimnich A, Salmena L, Sayama K, Hakem R, Peter M E. CD95 apoptosis resistance in certain cells can be overcome by noncanonical activation of caspase-8. Cell Death Differ, 2005, 12(1): 25–37CrossRefPubMedGoogle Scholar
  9. 9.
    Meli M, D’Alessandro N, Tolomeo M, Rausa L, Notarbartolo M, Dusonchet L. NF-κB Inhibiton Restores Sensitivity to Fas-Mediated Apoptosis in Lymphoma Cell Lines. Ann N Y Acad Sci, 2003, 1010: 232–236CrossRefPubMedGoogle Scholar
  10. 10.
    Buzyn A, Petit F, Ostankovitch M, Figueiredo S, Varet B, Guillet J G, Ameisen J C, Estaquier J. Membrane-bound Fas ligand on leukemic cells: a mechanism of tumor immune escape in leukemic patients. Blood, 1999, 94(9): 3135–3140PubMedGoogle Scholar
  11. 11.
    Barnhart B C, Legembre P, Pietras E, Bubici C, Franzoso G, Peter M E. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J, 2004, 23(15): 3175–3185CrossRefPubMedGoogle Scholar
  12. 12.
    Kavurma M M, Khachigian L M. Signaling and transcriptional control of Fas ligand gene expression. Cell Death Differ, 2003, 10(1): 36–44CrossRefPubMedGoogle Scholar
  13. 13.
    Savickiene J, Treigyte G, Magnusson K E, Navakauskiene R. p21 and FasL gene activation via Sp1 and NF-κB is required for leukemia cell survival but not for cell death induced by diverse stimuli. Int J Biochem Cell Biol, 2005, 37(4): 784–796CrossRefPubMedGoogle Scholar
  14. 14.
    Kater A P, Dicker F, Mangiola M, Welsh K, Houghten R, Ostresh J, Nefzi A, Reed J C, Pinilla C, Kipps T J. Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis. Blood, 2005, 106(5): 1742–1748CrossRefPubMedGoogle Scholar
  15. 15.
    Loeder S, Drensek A, Jeremias I, Debatin K M, Fulda S. Small molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95-induced apoptosis. Int J Cancer, 2009, 126(9): 2216–2228Google Scholar
  16. 16.
    Doyle B T, O’Neill A J, Newsholme P, Fitzpatrick J M, Watson R W. The loss of IAP expression during HL-60 cell differentiation is caspase-independent. J Leukoc Biol, 2002, 71(2): 247–254PubMedGoogle Scholar
  17. 17.
    Ohashi M, Iwase M, Nagumo M. Changes in susceptibility to Fas-mediated apoptosis during differentiation of HL-60 cells. J Leukoc Biol, 2000, 67(3): 374–380PubMedGoogle Scholar
  18. 18.
    Hao Z, Mak T W. Type I and Type II pathways of Fas-mediated apoptosis are differentially controlled by XIAP. J Mol Cell Biol, 2009 Oct 16 [Epub ahead of print]Google Scholar
  19. 19.
    Straszewski-Chavez S L, Abrahams V M, Aldo P B, Romero R, Mor G. AKT controls human first trimester trophoblast cell sensitivity to FAS-mediated apoptosis by regulating XIAP expression. Biol Reprod, 2010, 82(1): 146–152CrossRefPubMedGoogle Scholar
  20. 20.
    Blomberg J, Ruuth K, Santos D, Lundgren E. Acquired resistance to Fas/CD95 ligation in U937 cells is associated with multiple molecular mechanisms. Anticancer Res, 2008, 28(2A): 593–599PubMedGoogle Scholar
  21. 21.
    Qin Y, Auh S, Blokh L, Long C, Gagnon I, Hamann K J. TNF-alpha induces transient resistance to Fas-induced apoptosis in eosinophilic acute myeloid leukemia cells. Cell Mol Immunol, 2007, 4(1): 43–52PubMedGoogle Scholar
  22. 22.
    Fakler M, Loeder S, Vogler M, Schneider K, Jeremias I, Debatin K M, Fulda S. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood, 2009, 113(8): 1710–1722CrossRefPubMedGoogle Scholar
  23. 23.
    Morales J C, Ruiz-Magana M J, Ruiz-Ruiz C. Regulation of the resistance to TRAIL-induced apoptosis in human primary T lymphocytes: role of NF-kappaB inhibition. Mol Immunol, 2007, 44(10): 2587–2597CrossRefPubMedGoogle Scholar
  24. 24.
    Carter B Z, Mak D H, Schober W D, Dietrich M F, Pinilla C, Vassilev L T, Reed J C, Andreeff M. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood, 2008, 111(7): 3742–3750CrossRefPubMedGoogle Scholar

Copyright information

© Higher Education Press and Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  1. 1.Department of HematologyThe Central Hospital of WuhanWuhanChina
  2. 2.Department of Hematology, Union Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina

Personalised recommendations